MELPHALAN, YTTRIUM Y 90 IBRITUMOMAB TIUXETAN, AND RITUXIMAB FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TREATING OLDER PATIENTS WITH NON-HODGKIN'S LYMPHOMA THAT HAS RELAPSED OR NOT RESPONDED TO PREVIOUS TREATMENT: